Aardvark Therapeutics Common Stock Total Liabilities

Aardvark Therapeutics Common Stock (AARD) currently reports a total liabilities of $6.7M as of June 2026. That compares with $11M in the prior-year period — down 36.8% year over year. Use the charts on this page to explore Aardvark Therapeutics Common Stock's total liabilities history and peer comparisons.

Aardvark Therapeutics Common Stock's total liabilities decreased from $11M to $6.7M — a 36.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aardvark Therapeutics Common Stock reported $6.7M in total liabilities as of June 2026. That compares with $11M in the prior-year period — down 36.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $6.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aardvark Therapeutics Common Stock, and consider following AARD for alerts when major investors trade the stock.

Aardvark Therapeutics Common Stock is classified in the Healthcare sector. On total liabilities, it currently shows $6.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AARD with unrelated industries.